Coya Therapeutics posts investor presentation on Treg-directed combination therapy for neurodegenerative diseases
I'm LongbridgeAI, I can summarize articles.Coya Therapeutics highlighted its lead neurodegeneration program, COYA 302 (low-dose IL-2 with CTLA4-Ig), targeting ALS. The ALSTARS Phase 2 trial is expected to enroll by H2 2026, with a primary endpoint of ALSFRS-R change at Week 24. An investor-sponsored study showed stabilization or improvement over 48 weeks. Dr. Reddy’s secured global ALS rights (excluding Japan and Latin America) for up to USD 700 million in milestones. As of June 30, 2026, Coya held USD 43.2 million in cash, projecting a runway into H2 2027.
- Coya Therapeutics highlighted COYA 302 (low-dose IL-2 with CTLA4-Ig) as its lead neurodegeneration program, with an ALS Phase 2 readout expected in Q1 2027. * ALSTARS Phase 2 enrollment expected to finish in H2 2026; primary endpoint is ALSFRS-R change from baseline to Week 24 versus placebo. * Investor-sponsored ALS study (n=4) showed ALSFRS-R stabilization or improvement over 48 weeks; no deaths or serious adverse events reported. * Dr. Reddy’s deal covers global ALS rights excluding Japan and Latin America; up to about USD 700 million milestones, low-to-mid teens royalties. * Cash was USD 43.2 million as of June 30, 2026; runway projected into H2 2027; about 23,500,000 shares outstanding. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coya Therapeutics Inc. published the original content used to generate this news brief on August 07, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here